Compounds > moclobemide

moclobemide and scopolamine hydrobromide

moclobemide has been researched along with scopolamine hydrobromide in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's3 (42.86)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL1
Topliss, JG; Yoshida, F1
Bruno-Blanch, L; Gálvez, J; García-Domenech, R1
Lombardo, F; Obach, RS; Waters, NJ1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Anand, R; Lorscheid, T; Wesnes, K1
Chodera, A; Kus, K; Nowakowska, E; Rybakowski, J1

Trials

1 trial(s) available for moclobemide and scopolamine hydrobromide

ArticleYear
Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia.
    Acta psychiatrica Scandinavica. Supplementum, 1990, Volume: 360

    Topics: Adult; Alzheimer Disease; Antidepressive Agents; Attention; Benzamides; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Mental Recall; Moclobemide; Models, Neurological; Monoamine Oxidase Inhibitors; Scopolamine; Substance-Related Disorders

1990

Other Studies

6 other study(ies) available for moclobemide and scopolamine hydrobromide

ArticleYear
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat

2016
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
    Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16

    Topics: Anticonvulsants; Computer Simulation; Databases, Factual; Discriminant Analysis; Drug Design; Molecular Structure; Quantitative Structure-Activity Relationship

2003
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Anxiolytic and memory improving effects of moclobemide.
    Arzneimittel-Forschung, 1998, Volume: 48, Issue:6

    Topics: Animals; Anti-Anxiety Agents; Benzamides; Male; Memory; Moclobemide; Monoamine Oxidase Inhibitors; Motor Activity; Muscarinic Antagonists; Rats; Rats, Wistar; Scopolamine; Time Factors

1998